Monday, 20 May 2019

You are here

Omega-3 Rich Fish Lowers Gout Flares

Boston researchers have shown that consumption of fish rich in omega‐3 polyunsaturated fatty acids (n‐3 PUFA) leads to a lower risk of recurrent gout flares.

They used a novel internet‐based, case‐crossover study conducted from 2003‐2012 (the Boston University Online Gout Study). They questioned gout patients about gout flares, and during gout flare‐free periods their intake of n‐3 PUFA‐rich supplements and fish intake, total purine intake, diuretic use, and other arthritis and urate‐lowering medications (allopurinol, non‐steroidal anti‐inflammatory drugs, colchicine).

Of the 724 participants, 85% met the 1977 Preliminary ACR classification criteria for acute gout.

In all patients (flare and non-flare; n=724 patients), 22% reported ingesting form of n‐3 PUFA consumption (supplements: 4.6%; dietary fatty fish: 19%) in the prior 48 hours. 

While any ingestion of n-3 PUFA did not affect gout flares (aOR 1.01; 95% CI, 0.63‐1.60; p=0.98), those who had two or more servings of n‐3 PUFA‐rich fish had a lower risk of gout flares (aOR 0.74; 95% CI, 0.54‐0.99; p=0.04).

Supplement use with either Omega 3, cod liver oil or fish oil supplements did not lower the risk of recurrent gout flares.


The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Coexistent Gout Increases Risk in Rheumatoid Arthritis

It his often said that gout and rheumatoid arthritis (RA) cannot coexist and where confusion exists, a good history and testing for serum urate (SUA) and rheumatoid factor (RF) can usually clarify the dominant disorders. A recent study shows that hyperuricemia and gout are uncommon in RA, but when present shows an increased risk of comorbidities and cardiovascular (CV) mortality.

Less Structural Damage with T2T in Gout

A two‐year randomized clinical trial has demonstrated that allopurinol dose escalation to a target serum urate (SU) results in less bone erosion, structural damage and urate crystal deposition in patients with gout.

Ideal Outcomes are Seldom Achieved in Gout

Studies from a cohort of gout patients in Mexico shows that long-term goals of a target serum urate (sUA) < 6 mg/dL and remission are rare, especially for those with severe gout.

Chronic Kidney Disease Augments Gout Risks

A population based cohort analysis shows that patients with incident gout and chronic kidney disease (CKD) have far worse outcomes than those without CKD.

A retrospective population-based cohort study of incident gout between 2006-2009 identified those with CKD; defined as a pre-existing diagnosis of chronic kidney disease, chronic renal failure, kidney transplantation, or dialysis at index date.

Ironwood Retreats from the US Gout Market

Ironwood Pharmaceuticals discontinued the marketing and sales of both lesinurad (Zurampic) the combination drug of lesinurad and allopurinol (Duzallo) in the United States effective February 1, 2019. In addition the Duzallo and Zurampic Patient Savings Program were also discontinued on December 31, 2018.

The company stated that this was a financial decision unrelated to the efficacy or safety of lesinurad.